Related Experiment Videos
Real-world venetoclax dosing patterns and treatment persistence in patients with acute myeloid leukemia: a community
Yuki Goshima1,2, Tomoya Saika3,4, Yuki Kado3
1Department of Hematology, Nippon Medical School, Tokyo, Japan.
Abstract:
Venetoclax (VEN)-based regimens are widely used for patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, but VEN dosing patterns and their relation to treatment persistence are not well described. We conducted a retrospective longitudinal study using de-identified dispensing records from Japanese community pharmacies to characterize VEN dosing patterns and treatment persistence in routine practice. Patients (n = 162) were clustered by mean daily VEN dose and dosing frequency, yielding four groups defined by high versus low dose and high versus low frequency. Treatment persistence was longer in the low-frequency clusters, where there was a clearer association with dosing frequency than with mean daily dose. Strong CYP3A4 inhibitor use was more common in low-dose clusters, consistent with dose adjustment when strong inhibitors are coadministered. These findings highlight heterogeneous real-world VEN use and its implications for treatment persistence.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Dosage Regimens: Partial Pharmacokinetic Parameters
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Treatment Resistent Cancers
Pharmacokinetics in Pediatric Patients: Drug Distribution